Therapeutics News and Research

RSS

REVEAL trial: VASCAZEN meets primary endpoint

Pivotal Therapeutics Inc., a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease and overall health, is pleased to announce that VASCAZEN met its primary endpoint in the REVEAL trial.

10 Apr 2013

Bayer HealthCare and German Cancer Research Center to extend strategic alliance in search of novel cancer therapeutics

Bayer HealthCare (Bayer) and the German Cancer Research Center (DKFZ) will extend their successful strategic research alliance in search of novel cancer therapeutics by focusing their activities also on the field of immunotherapy. Immunotherapies are a promising approach to treat cancer with the aim to selectively reactivate the body's own immune system so that it attacks tumor cells.

10 Apr 2013

Onconova reports positive results from rigosertib Phase 1 trial in patients with advanced solid tumors

Onconova Therapeutics, Inc., a development-stage pharmaceutical company focused on discovering and developing novel small molecule drug products to treat cancer, today announced that tolerability and favorable anti-tumor activity data from a Phase 1 trial evaluating oral rigosertib, a dual pathway inhibitor, in patients with advanced solid tumors including refractory metastatic head and neck cancer were presented today at the American Association for Cancer Research Annual Meeting.

10 Apr 2013

BIND Therapeutics presents positive Phase 1 clinical study results for BIND-014 at AACR meeting

BIND Therapeutics, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called AccurinsTM, announced today that positive Phase 1 clinical data for BIND-014, the company's lead drug candidate, were presented today in an oral presentation at the American Association for Cancer Research 2013 Annual Meeting.

10 Apr 2013

Research offers new understanding related to effects of chemical conjugation on stability of ADCs

Wolfe Laboratories today announced the presentation of an abstract related to its research efforts surrounding antibody-drug conjugates at the 245th National Meeting of the American Chemical Society, held April 7-11 in New Orleans.

9 Apr 2013

MD Anderson professor to receive award for clinical research excellence at AACR meeting

Hagop Kantarjian, M.D., chair and professor in The University of Texas MD Anderson Cancer Center's Department of Leukemia, will be honored for clinical research excellence at the AACR Annual Meeting 2013, April 6-10.

9 Apr 2013

Weill Cornell Medical College sets up new Feil Family Brain and Mind Research Institute

Weill Cornell Medical College has established the new Feil Family Brain and Mind Research Institute, a unique, multidisciplinary translational neuroscience research hub. Named in honor of long-time benefactors Gertrude and Louis Feil, the institute was created with a generous $28 million gift from the Feil Family.

9 Apr 2013

Roche, Isis Pharmaceuticals to develop neurodegenerative therapeutics for Huntington's disease

Roche and Isis Pharmaceuticals, Inc today announced that they have formed an alliance to develop treatments for Huntington's disease based on Isis' antisense oligonucleotide technology.

9 Apr 2013

Blood test reveals more gene mutations in cancer than traditional tumor biopsy

A new blood test revealed more of the gene mutations that sustain certain digestive-tract tumors than did a DNA analysis of a traditional tumor biopsy, Dana-Farber Cancer Institute investigators will report at a special symposium of the American Association for Cancer Research annual meeting in Washington, April 6-10.

8 Apr 2013

Sorrento Therapeutics, IGDRASOL to present updates on Cynviloq at Nanomedicine 2013 meeting

Sorrento Therapeutics, Inc. and IGDRASOL announced today that IGDRASOL will be presenting updates of its analysis of proprietary late clinical stage NBN-Pac formulations, namely IG-001 (Cynviloq) and IG-004 (a D-a-tocopheryl polyethylene glycol succinate (TPGS)-based paclitaxel formulation) at the annual Nanomedicine 2013 meeting in Barcelona, Spain (April 11th - 12th).

8 Apr 2013

GenSight Biologics announces closing of €32 million Series A financing

GenSight Biologics, a biopharmaceutical company focused on the development of ophthalmic therapeutics using gene therapy, announced today the closing of a €32 million Series A financing.

8 Apr 2013

Nektar Therapeutics presents positive results for NKTR-214 at AACR Annual Meeting

Nektar Therapeutics today presented positive preclinical data for NKTR-214, a novel cancer immunotherapy which targets the IL-2 receptor complex, at the 2013 American Association for Cancer Research Annual Meeting.

8 Apr 2013

A*STAR's professor receives Szent-Gy-rgyi prize for groundbreaking cancer pill

Professor Alex Matter, Chief Executive Officer of A*STAR's Experimental Therapeutics Centre (ETC), has been awarded the 8th Annual Szent-Gy-rgyi Prize for Progress in Cancer Research by the National Foundation for Cancer Research (NFCR) for his contributions to the development of the first drug specifically targeting a molecular lesion in cancer.

7 Apr 2013

Spencer Trask applauds InVivo for getting FDA approval to test biopolymer scaffold in humans

Spencer Trask, a venture capital firm focused on developing big ideas into world-changing companies, congratulates InVivo Therapeutics, for its recent approvals from the U.S. Food and Drug Administration.

6 Apr 2013

FDA approves InVivo Therapeutics' IDE to test biopolymer scaffold product in humans

InVivo Therapeutics Holdings Corp., a developer of groundbreaking technologies for the treatment of spinal cord injuries and other neurotrauma conditions, today announced that the U.S. Food and Drug Administration has approved the Company's Investigational Device Exemption to begin human studies to test its biopolymer scaffold product, a technology developed to treat patients with acute, traumatic SCI.

5 Apr 2013

UNC study shows promise for uncovering true mechanisms of human stem cell biology

For the first time, researchers at the University of North Carolina at Chapel Hill have isolated adult stem cells from human intestinal tissue.

5 Apr 2013

UC San Francisco researchers outline cell-based therapeutics as a "third pillar” of medicine

Treating patients with cells may one day become as common as it is now to treat the sick with drugs made from engineered proteins, antibodies or smaller chemicals, according to UC San Francisco researchers.

4 Apr 2013

InVivo Therapeutics obtains HUD designation from FDA for spinal cord injury treatment

InVivo Therapeutics Holdings Corp., a developer of groundbreaking technologies for the treatment of spinal cord injuries and other neurotrauma conditions, today announced that the Company has received approval for its request filed with the U.S. Food and Drug Administration for Humanitarian Use Device designation for its biopolymer scaffolding product.

4 Apr 2013

Polymer scaffolds can advance the development of cancer therapeutics

Porous polymer scaffolds fabricated to support the growth of biological tissue for implantation may hold the potential to greatly accelerate the development of cancer therapeutics.

3 Apr 2013

BIND Therapeutics and Pfizer sign collaboration agreement to develop, commercialize Accurins

BIND Therapeutics, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called Accurins, announced today that it has entered into a global collaboration agreement with Pfizer Inc. to develop and commercialize Accurins utilizing select small molecule targeted therapies.

3 Apr 2013

Therapeutics News and Research

REVEAL trial: VASCAZEN meets primary endpoint

Bayer HealthCare and German Cancer Research Center to extend strategic alliance in search of novel cancer therapeutics

Onconova reports positive results from rigosertib Phase 1 trial in patients with advanced solid tumors

BIND Therapeutics presents positive Phase 1 clinical study results for BIND-014 at AACR meeting

Research offers new understanding related to effects of chemical conjugation on stability of ADCs

MD Anderson professor to receive award for clinical research excellence at AACR meeting

Weill Cornell Medical College sets up new Feil Family Brain and Mind Research Institute

Roche, Isis Pharmaceuticals to develop neurodegenerative therapeutics for Huntington's disease

Blood test reveals more gene mutations in cancer than traditional tumor biopsy

Sorrento Therapeutics, IGDRASOL to present updates on Cynviloq at Nanomedicine 2013 meeting

GenSight Biologics announces closing of €32 million Series A financing

Nektar Therapeutics presents positive results for NKTR-214 at AACR Annual Meeting

A*STAR's professor receives Szent-Gy-rgyi prize for groundbreaking cancer pill

Spencer Trask applauds InVivo for getting FDA approval to test biopolymer scaffold in humans

FDA approves InVivo Therapeutics' IDE to test biopolymer scaffold product in humans

UNC study shows promise for uncovering true mechanisms of human stem cell biology

UC San Francisco researchers outline cell-based therapeutics as a "third pillar” of medicine

InVivo Therapeutics obtains HUD designation from FDA for spinal cord injury treatment

Polymer scaffolds can advance the development of cancer therapeutics

BIND Therapeutics and Pfizer sign collaboration agreement to develop, commercialize Accurins

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News